Quantum BioPharma to Showcase Lucid-MS at ArcStone-Kingswood Growth Summit
Event summary
- Quantum BioPharma will present at the ArcStone-Kingswood Growth Summit in Toronto on September 16, 2026.
- Anthony Durkacz, Co-founder and Executive Co-chairman, will discuss recent milestones and future growth strategy.
- The company recently received FDA approval for Phase 2 trials of Lucid-MS, a novel treatment for progressive multiple sclerosis.
- Lucid-MS targets neurodegeneration, differentiating it from existing immune-focused MS therapies.
- Quantum BioPharma retains 19.48% ownership of Unbuzzd Wellness Inc., with potential royalty payments up to $250 million.
The big picture
Quantum BioPharma's participation in the ArcStone-Kingswood Growth Summit comes at a critical juncture, following FDA approval for Lucid-MS Phase 2 trials. The company is positioning itself as a leader in neurodegenerative treatments, targeting unmet medical needs in a rapidly growing market. Its strategic focus on differentiated mechanisms, such as neuroprotection in MS, aligns with broader industry trends toward addressing disease root causes rather than symptoms.
What we're watching
- Clinical Progress
- The pace at which Lucid-MS advances through Phase 2 trials will determine its market potential in the $38.62 billion MS therapeutics space.
- Investor Interest
- Whether Quantum BioPharma can leverage the ArcStone-Kingswood Growth Summit to attract significant investment for its neurodegenerative and metabolic disorder pipeline.
- Royalty Revenue
- How Unbuzzd Wellness Inc.'s commercial success will impact Quantum BioPharma's royalty income, particularly as it approaches the $250 million threshold.